4,6-Dichloro-2-Methylpyrimidine CAS 1780-26-3 Purity ≥99.5% (GC) Factory Hot Sale
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com
Chemical Name | 4,6-Dichloro-2-Methylpyrimidine |
Mashoko anoreva zvakafanana | 2-Methyl-4,6-Dichloropyrimidine;2,4-Dichloro-6-Methylpyrimidine |
Nhamba yeCAS | 1780-26-3 |
Nhamba yeCAT | RF-PI687 |
Stock Status | MuStock, Kugadzirwa Kunokwira Kusvika Matani |
Molecular Formula | C5H4Cl2N2 |
Molecular Weight | 163.00 |
Melting Point | 41.5 ~ 45.5 ℃ (lit.) |
Solubility (Soluble in) | Methanol |
Brand | Ruifu Chemical |
Item | Zvinotsanangurwa |
Chitarisiko | Ichena kana Isina-White Crystalline Powder |
Kuchena / Analysis Method | ≥99.5% (GC) |
Kurasika paKuomesa | ≤0.50% |
Residue paIgnition | ≤0.20% |
Kusachena Kumwechete | ≤0.50% |
Zvose Zvisina Kuchena | ≤0.50% |
Test Standard | Enterprise Standard |
Usage | Pharmaceutical Intermediate;Dasatinib/Moxonidine Pakati |
4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) Nzira Yekuita
Package: Bhodhoro, Aluminium foil bag, 25kg/Cardboard Drum, kana zvinoenderana nezvinodiwa nemutengi.
Storage Condition:Chengetedza mumidziyo yakavharwa panzvimbo inotonhorera uye yakaoma;Dzivirira kubva kuchiedza uye unyoro
4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) inoshandiswa mukugadzirwa kwemishonga yepakati uye APIs.Kugadzirira Zvigadzirwa: Moxonidine (CAS: 75438-57-2);Dasatinib (CAS: 302962-49-8);Dasatinib Monohydrate (CAS: 863127-77-9);4-Chloro-2,6-Dimethylpyrimidine (CAS: 4472-45-1);4-Amino-6-Chloro-2-Methylpyrimidine (CAS: 1749-68-4).Moxonidine rudzi rutsva rwemishonga inorwisa hypertensive, inowanzoshandiswa mukurapa yakakosha hypertension.Kuenzaniswa nevakuru vepakati-vanoita antihypertensives, Moxonidine inosunga nekubatana kukuru kune imidazoline I1-receptor pane α2-receptor.Dasatinib ndeyemuromo ine simba oncogenic kinase inhibitor, inogona kuvharidzira chiratidzo chekenza cell replication kukurumidza, muna Chivabvu 2009, iyo US Food and Drug Administration (FDA) yakabvumidza zviri pamutemo kutengeswa kwedasatinib, yakashandiswa mukurapa kurapwa kweakasiyana asingaperi. myeloid leukemia (CML), kusanganisira kurapwa kwechronic myeloid leukemia iyo inopesana kana kushivirira kune zvirongwa zvekurapa zvinosanganisira imatinib mesylate., Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) uye kurapwa kwevarwere vane zviputi zvakasimba.